Format
Items per page
Sort by

Send to:

Choose Destination

Results: 18

1.

The value of nature's natural product library for the discovery of New Chemical Entities: the discovery of ingenol mebutate.

Ogbourne SM, Parsons PG.

Fitoterapia. 2014 Oct;98:36-44. doi: 10.1016/j.fitote.2014.07.002. Epub 2014 Jul 10.

PMID:
25016953
2.

Permanent genetic resources added to molecular ecology resources database 1 April 2013-31 May 2013.

Molecular Ecology Resources Primer Development Consortium, Agostini C, Albaladejo RG, Aparicio A, Arthofer W, Berrebi P, Boag PT, Carbone I, Conroy GC, Cortesero AM, Costa Gonçalves E, Costa D, Couto A, De Girolamo M, Du H, Fu SJ, Garrido-Garduño T, Gettová L, Gilles A, Guerreiro Hamoy I, Herrera CM, Heussler C, Isidro E, Josso C, Krapf P, Lamont RW, Le Ralec A, Lopes S, Luís C, Luo H, Mahéo F, Marino IA, Mieuzet L, Murray BW, Ogbourne SM, Pallavicini A, Parejo-Farnés C, Patarnello T, Paty C, Pereira C, Pinho C, Pinto P, Poinsot D, Powell A, Putman AI, Santoro A, Santos S, Schlick-Steiner BC, Scott C, Silvanira Barbosa M, Šimková A, Simon JC, Solé-Cava A, Steiner FM, Sun Z, Torboli V, Tredway LP, Van Coeverden de Groot PJ, Vasconcellos A, Vázquez-Domínguez E, Wang DQ, Wang YX, Wei QW, Zane L, Zhang SH.

Mol Ecol Resour. 2013 Sep;13(5):966-8. doi: 10.1111/1755-0998.12140.

PMID:
23937578
3.

Effective treatment of squamous cell carcinomas with ingenol mebutate gel in immunologically intact SKH1 mice.

Cozzi SJ, Le TT, Ogbourne SM, James C, Suhrbier A.

Arch Dermatol Res. 2013 Jan;305(1):79-83. doi: 10.1007/s00403-012-1270-0. Epub 2012 Aug 8.

4.

Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches.

Cozzi SJ, Ogbourne SM, James C, Rebel HG, de Gruijl FR, Ferguson B, Gardner J, Lee TT, Larcher T, Suhrbier A.

J Invest Dermatol. 2012 Apr;132(4):1263-71. doi: 10.1038/jid.2011.418. Epub 2011 Dec 22.

5.

PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial.

Siller G, Rosen R, Freeman M, Welburn P, Katsamas J, Ogbourne SM.

Australas J Dermatol. 2010 May;51(2):99-105. doi: 10.1111/j.1440-0960.2010.00626.x.

PMID:
20546215
6.

Immunostimulatory cancer chemotherapy using local ingenol-3-angelate and synergy with immunotherapies.

Le TT, Gardner J, Hoang-Le D, Schmidt CW, MacDonald KP, Lambley E, Schroder WA, Ogbourne SM, Suhrbier A.

Vaccine. 2009 May 18;27(23):3053-62. doi: 10.1016/j.vaccine.2009.03.025. Epub 2009 Apr 3.

PMID:
19428919
7.

PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study.

Siller G, Gebauer K, Welburn P, Katsamas J, Ogbourne SM.

Australas J Dermatol. 2009 Feb;50(1):16-22. doi: 10.1111/j.1440-0960.2008.00497.x.

PMID:
19178487
8.

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells.

Benhadji KA, Serova M, Ghoul A, Cvitkovic E, Le Tourneau C, Ogbourne SM, Lokiec F, Calvo F, Hammel P, Faivre S, Raymond E.

Br J Cancer. 2008 Dec 2;99(11):1808-15. doi: 10.1038/sj.bjc.6604642.

9.

Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells.

Serova M, Ghoul A, Benhadji KA, Faivre S, Le Tourneau C, Cvitkovic E, Lokiec F, Lord J, Ogbourne SM, Calvo F, Raymond E.

Mol Cancer Ther. 2008 Apr;7(4):915-22. doi: 10.1158/1535-7163.MCT-07-2060.

10.

Proceedings of the First International Conference on PEP005.

Ogbourne SM, Hampson P, Lord JM, Parsons P, De Witte PA, Suhrbier A.

Anticancer Drugs. 2007 Mar;18(3):357-62.

PMID:
17264770
11.

Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate.

Challacombe JM, Suhrbier A, Parsons PG, Jones B, Hampson P, Kavanagh D, Rainger GE, Morris M, Lord JM, Le TT, Hoang-Le D, Ogbourne SM.

J Immunol. 2006 Dec 1;177(11):8123-32.

12.
13.

Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death.

Ogbourne SM, Suhrbier A, Jones B, Cozzi SJ, Boyle GM, Morris M, McAlpine D, Johns J, Scott TM, Sutherland KP, Gardner JM, Le TT, Lenarczyk A, Aylward JH, Parsons PG.

Cancer Res. 2004 Apr 15;64(8):2833-9.

14.

Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif.

Darnell GA, Antalis TM, Johnstone RW, Stringer BW, Ogbourne SM, Harrich D, Suhrbier A.

Mol Cell Biol. 2003 Sep;23(18):6520-32.

15.

Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis.

Aimes RT, Zijlstra A, Hooper JD, Ogbourne SM, Sit ML, Fuchs S, Gotley DC, Quigley JP, Antalis TM.

Thromb Haemost. 2003 Mar;89(3):561-72.

PMID:
12624642
16.
17.

Localization, expression and genomic structure of the gene encoding the human serine protease testisin.

Hooper JD, Bowen N, Marshall H, Cullen LM, Sood R, Daniels R, Stuttgen MA, Normyle JF, Higgs DR, Kastner DL, Ogbourne SM, Pera MF, Jazwinska EC, Antalis TM.

Biochim Biophys Acta. 2000 Jun 21;1492(1):63-71.

PMID:
11004480
18.

Cloning of the cDNA and localization of the gene encoding human NRBP, a ubiquitously expressed, multidomain putative adapter protein.

Hooper JD, Baker E, Ogbourne SM, Sutherland GR, Antalis TM.

Genomics. 2000 May 15;66(1):113-8.

PMID:
10843813
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk